OptiBiotix Health PLC Online distribution agreement - SlimBiome® Medical (8881F)
18 Julio 2019 - 01:00AM
UK Regulatory
TIDMOPTI
RNS Number : 8881F
OptiBiotix Health PLC
18 July 2019
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Online distribution agreement for SlimBiome(R) Medical
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, cardiovascular disease and
diabetes, announces it has signed an agreement with BioEnergiser
Ltd. ("BioEnergiser") for the online distribution of SlimBiome(R)
Medical in the UK. SlimBiome(R) Medical is a CE marked medical
device which independent clinical studies show reduces hunger,
cravings for sweet and savoury foods, and fat intake. These
functionalities help people who consume SlimBiome(R) Medical to
modify the type and amount of food they eat, helping them to
moderate their calorie intake and achieve sustainable weight
loss.
The agreement grants BioEnergiser rights to distribute
SlimBiome(R) Medical online within the UK whilst allowing
OptiBiotix to continue to sell the product on its online store
(Optibiotix.online). This agreement provides market exclusivity
linked to minimum sales orders to be agreed after a review of
sales, pricing, and future forecasts, six months after signing this
agreement.
Founded in 1985, BioEnergiser is an established UK sales and
marketing company specialising in consumer goods supplying retail,
mail order, direct to TV and home shopping channels. BioEnergiser
bring expertise in direct to consumer sales and marketing through
mainstream digital and satellite TV and radio commercials, and
advertising in national newspapers and magazines. They have a track
record of rapidly growing online sales with a recent product launch
approaching GBP1.6m sales within the first year. Whilst there is no
guarantee sales performance with other products can be replicated
with SlimBiome(R) Medical we believe this demonstrates
BioEnergisers experience in quickly building online sales in the
healthcare market. BioEnergiser's commitment to consumer marketing
is evidenced by their spend across their product range in print
media alone of GBP5.1m in 2018.
This agreement is a strategic step to take OptiBiotix's own
label product (SlimBiome(R) Medical) direct to the UK consumer to
enhance their online consumer health presence. This strategy helps
build brand awareness, complementing any potential launch of
products with major retailers, and creates demand for its
functional ingredients (SlimBiome(R) and LP(LDL) (R)) in a wide
range of products across the world.
Dr. Fred Narbel, Managing Director of OptiBiotix's prebiotics
division commented: "We are pleased to announce this deal with
BioEnergiser to distribute SlimBiome(R) Medical online in the UK.
This is a significant and exciting step in accelerating the growth
of OptiBiotix consumer health division. BioEnergiser's expertise in
direct to consumer online sales and marketing will help build brand
and consumer awareness of SlimBiome(R) Medical through TV and
national newspaper advertising, complementing any potential future
retail launch. The deal brings further value by providing us with
economies of scale and will support revenue growth and
profitability of OptiBiotix's prebiotics division going
forward."
Steve Simmonds, Managing Director of BioEnergiser commented: "We
are pleased to be working with OptiBiotix Health. The partnership
brings together OptiBiotix's award winning CE marked SlimBiome(R)
Medical with its IP portfolio and consumer and clinical studies,
with BioEnergiser's sales and marketing expertise. We believe this
to be a great fit and hope to be able to replicate the rapid sales
growth we have seen with a number of recent product launches with
SlimBiome(R) Medical."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD)
Liam Murray / Jo Turner / Ludovico Lazzaretti Tel: 020 7213 0880
finnCap (Broker)
Geoff Nash / Kate Bannatyne (Corporate Finance)
Tel: 020 7220 0500
Camille Gochez (Corporate Broking)
goetzpartners securities Limited Tel: 0203 859 7725
Ulrich Kinzel
Walbrook PR Ltd
Anna Dunphy Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D program working with leading
academics in the development of microbial strains, compounds, and
formulations which are used as active ingredients and supplements.
More than twenty international food and healthcare supplement
companies have signed agreements with OptiBiotix to incorporate
their human microbiome modulators into a wide range of food
products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGRZMGMNKNFGLZM
(END) Dow Jones Newswires
July 18, 2019 02:00 ET (06:00 GMT)
Optibiotix Health (LSE:OPTI)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Optibiotix Health (LSE:OPTI)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024